WO2000010613A3 - Inhibition of smooth muscle cell migration by heme oxygenase 1 - Google Patents

Inhibition of smooth muscle cell migration by heme oxygenase 1 Download PDF

Info

Publication number
WO2000010613A3
WO2000010613A3 PCT/US1999/019245 US9919245W WO0010613A3 WO 2000010613 A3 WO2000010613 A3 WO 2000010613A3 US 9919245 W US9919245 W US 9919245W WO 0010613 A3 WO0010613 A3 WO 0010613A3
Authority
WO
WIPO (PCT)
Prior art keywords
heme oxygenase
smooth muscle
inhibition
cell migration
muscle cell
Prior art date
Application number
PCT/US1999/019245
Other languages
French (fr)
Other versions
WO2000010613A2 (en
Inventor
Gary J Nabel
Elizabeth G Nabel
Original Assignee
Univ Michigan
Gary J Nabel
Elizabeth G Nabel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Gary J Nabel, Elizabeth G Nabel filed Critical Univ Michigan
Priority to DE69931376T priority Critical patent/DE69931376T2/en
Priority to AU56877/99A priority patent/AU5687799A/en
Priority to CA002343575A priority patent/CA2343575C/en
Priority to EP99943865A priority patent/EP1109914B1/en
Publication of WO2000010613A2 publication Critical patent/WO2000010613A2/en
Publication of WO2000010613A3 publication Critical patent/WO2000010613A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present method provides a method for inhibiting restenosis associated with mechanical injury of a blood vessel. Human heme oxygenase (I) (HO1) is directly administered at the site of injury. The present inventors have discovered that carbon monoxide generated by HO1 is involved in the molecular pathogenesis of vascular proliferative disorders. By using adenoviral-mediated expression of inducible heme oxygenase 1 in primary vascular smooth muscle cells (vsmc) in vivo, the present inventors demonstrate that in vivo expression of HO1 can be used to treat restenosis.
PCT/US1999/019245 1998-08-21 1999-08-21 Inhibition of smooth muscle cell migration by heme oxygenase 1 WO2000010613A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE69931376T DE69931376T2 (en) 1998-08-21 1999-08-21 HEM-OXYGENASE 1 FOR INHIBITING SMOOTH MUSCLE CELL MIGRATION
AU56877/99A AU5687799A (en) 1998-08-21 1999-08-21 Inhibition of smooth muscle cell migration by heme oxygenase
CA002343575A CA2343575C (en) 1998-08-21 1999-08-21 Inhibition of smooth muscle cell migration by heme oxygenase 1
EP99943865A EP1109914B1 (en) 1998-08-21 1999-08-21 Heme oxygenase 1 for the inhibition of smooth muscle cell migration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9770798P 1998-08-21 1998-08-21
US60/097,707 1998-08-21

Publications (2)

Publication Number Publication Date
WO2000010613A2 WO2000010613A2 (en) 2000-03-02
WO2000010613A3 true WO2000010613A3 (en) 2000-07-06

Family

ID=22264750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019245 WO2000010613A2 (en) 1998-08-21 1999-08-21 Inhibition of smooth muscle cell migration by heme oxygenase 1

Country Status (6)

Country Link
US (1) US6203991B1 (en)
EP (1) EP1109914B1 (en)
AU (1) AU5687799A (en)
CA (1) CA2343575C (en)
DE (1) DE69931376T2 (en)
WO (1) WO2000010613A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US7238673B2 (en) * 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
AU9463401A (en) 2000-10-16 2002-04-29 Conor Medsystems Inc Expandable medical device for delivery of beneficial agent
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
WO2002081634A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Imaging nucleic acid delivery
CA2445969A1 (en) * 2001-04-30 2002-11-07 Cell Genesys, Inc. Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
WO2002098432A1 (en) * 2001-06-01 2002-12-12 The Brigham And Women's Hospital, Inc. Methods of treating cardiac disorders
DE60229848D1 (en) * 2001-06-21 2008-12-24 Beth Israel Hospital - AND ORGANTRANSPLANTATIONS AND SUPPRESSING APOPTOSIS
US20030100889A1 (en) * 2001-07-05 2003-05-29 Nicolas Duverger Method of administration of a gene of interest to a vascular tissue
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
SG148850A1 (en) * 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
EP1499333B1 (en) * 2002-04-15 2015-06-24 University of Pittsburgh - Of the Commonwealth System of Higher Education Carbon monoxide for use in a method of treating ileus
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
CA2481786A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
MXPA04011426A (en) 2002-05-17 2005-10-19 Univ Yale Methods of treating hepatitis.
UA87438C2 (en) * 2002-06-05 2009-07-27 Йельский Университет Method for treatment or prophylaxis of cancer, method for performing of surgical operation for cancer ablation and us of carbon monooxide
US20040131703A1 (en) * 2002-06-21 2004-07-08 Bach Fritz H. Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
AU2004226327A1 (en) 2003-03-28 2004-10-14 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
WO2006029046A2 (en) * 2004-09-03 2006-03-16 Yale University Use of leptin in wound healing
EP1790350A1 (en) * 2005-11-24 2007-05-30 Interstitial Therapeutics Use of keratinocyte composition for the treatment of restenosis
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
ES2628634T3 (en) 2011-07-21 2017-08-03 Alfama, Inc. Carbon monoxide-ruthenium releasing molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABRAHAM ET AL: "Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: protective effect against heme and hemoglobin toxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, no. 92, July 1995 (1995-07-01), pages 6798 - 6802-6802, XP002100374, ISSN: 0027-8424 *
ABRAHAM N G ET AL: "Adenovirus-mediated heme oxygebase-1 gene transfer into rabbit ocular tissues", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE,US,ASSOCIATION FOR RESEARCH IN VISION AND, vol. 36, no. 11, 1 October 1995 (1995-10-01), pages 2202 - 2210, XP002086227, ISSN: 0146-0404 *
DUCKERS, HENRICUS J. (1) ET AL: "Protective properties of recombinant heme oxygenase 1 in vitro and in vivo in the balloon injured porcine artery.", CIRCULATION, (OCT. 27, 1998) VOL. 98, NO. 17 SUPPL., PP. I739-I740. MEETING INFO.: 71ST SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION DALLAS, TEXAS, USA NOVEMBER 8-11, 1998 THE AMERICAN HEART ASSOCIATION., XP000876603 *
MORITA T ET AL: "Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells", JOURNAL OF BIOLOGICAL CHEMISTRY, (26 DEC 1997) VOL. 272, NO. 52, PP. 32804-32809. PUBLISHER: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814. ISSN: 0021-9258., CHILDRENS HOSP, JOINT PROGRAM NEONATOL, 300 LONGWOOD AVE, ENDERS 9, BOSTON, MA 02115 (Reprint);HARVARD UNIV, SCH MED, DEPT PEDIAT, JOINT PROGRAM NEONATOL, BOSTON, MA 02115; BOSTON UNIV, MED CTR, DEPT , XP002133627 *
MORITA T ET AL: "Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide.", JOURNAL OF CLINICAL INVESTIGATION, (1995 DEC) 96 (6) 2676-82., XP000876619 *
NABEL ET AL: "RECOMBINANT GENE EXPRESSION IN VIVO WITHIN ENDOTHELIAL CELLS OF THE ARTERIAL WALL", SCIENCE, vol. 244, 1989, pages 1342 - 1344, XP002133629 *
NABEL ET AL: "SITE-SPECIFIC GENE EXPRESSION IN VIVO BY DIRECT GENE TRANSFER INTO THE ARTERIAL WALL", SCIENCE, vol. 249, 1990, pages 1285 - 1288, XP002133628 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Also Published As

Publication number Publication date
WO2000010613A2 (en) 2000-03-02
DE69931376D1 (en) 2006-06-22
CA2343575C (en) 2008-08-05
CA2343575A1 (en) 2000-03-02
US6203991B1 (en) 2001-03-20
EP1109914A2 (en) 2001-06-27
AU5687799A (en) 2000-03-14
EP1109914B1 (en) 2006-05-17
DE69931376T2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2000010613A3 (en) Inhibition of smooth muscle cell migration by heme oxygenase 1
Aiyar et al. Role of chromium (V), glutathione thiyl radical and hydroxyl radical intermediates in Chromium (VI)‐induced DNA Damage
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
ATE218164T1 (en) INHIBITION OF REPRODUCTION OF ARTERIAL SMOOTH MUSCLE CELLS
MXPA02007639A (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure.
ES2164841T3 (en) DERIVATIVES OF BENZOIMIDAZOL, ITS PREPARATION AND ITS THERAPEUTIC USES.
EP1618898A3 (en) Methods for regulating angiogenesis
HK1059439A1 (en) Compounds having activity as inhibitors of cytochrome p450rai
WO2001007026A3 (en) Improved method of treating type ii diabetes and obesity
IL86865A0 (en) Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
Sivrikaya et al. The effect of diclofenac sodium and papaverine on isolated human ureteric smooth muscle
CA2347178A1 (en) Methods of inhibiting smooth muscle cell proliferation and preventing restenosis with a vector expressing rb2/p130
HK1046094A1 (en) Ppar delta inhibitors for the treatment of cardiovascular diseases
McMahon et al. Methamphetamine-induced insulin release
PL331104A1 (en) Therapeutic application of bam (cd40l) technology in treating diseases related to smooth muscles
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
Keung A genuine organ specific alcohol dehydrogenase from hamster testes: Isolation, characterization and developmental changes
Shen Inhibition of dihydropteridine reductase by catecholamines and related compounds
WO1999043308A3 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
Kasemset et al. Regulation of Mn-SOD activity in the mouse heart: Glucose effect
JPS5645198A (en) Determination of amount of hydrogen peroxide of activity of peroxidase
JPS53108838A (en) Austenitic stainless steel welded joint
WO2002085376A3 (en) A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2343575

Country of ref document: CA

Ref country code: CA

Ref document number: 2343575

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 56877/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999943865

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999943865

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999943865

Country of ref document: EP